









Markets
/
Stocks
/
nasdaq-prta
/

Prothena Corporation PLC

PRTA

View Detailed Chart

6.810USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

366.56MMarket Cap

LossP/E TTM



Prothena Corporation PLC

6.810

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-0.87%

5 Days

+1.95%

1 Month

+5.83%

6 Months

-49.33%

Year to Date

-50.83%

1 Year

-67.80%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

HOLD

Current Rating

24.286

Target Price

256.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Prothena Corporation PLC

PRTA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(6)

Neutral(2)

Buy(5)

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.067

Buy

RSI(14)

59.648

Neutral

STOCH(KDJ)(9,3,3)

56.710

Sell

ATR(14)

0.324

High Vlolatility

CCI(14)

40.658

Neutral

Williams %R

44.444

Buy

TRIX(12,20)

0.526

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.872

Sell

MA10

6.732

Buy

MA20

6.569

Buy

MA50

5.974

Buy

MA100

8.143

Sell

MA200

11.615

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Ticker SymbolPRTA

CompanyProthena Corporation PLC

CEODr. Gene G. Kinney, Ph.D.

Websitehttps://www.prothena.com/